Rituximab therapy

Rituximab therapy is a B-cell-directed intervention for HCV-related mixed cryoglobulinemia and cryoglobulinemic membranoproliferative glomerulonephritis. Its decisive significance is that it addresses the downstream immune process rather than relying only on elimination of HCV: by targeting CD20-positive B cells, it can reduce cryoglobulin production and renal injury without the viral flare described with older immunosuppressive regimens.

Rationale and Therapeutic Target

HCV infection is a systemic disease that can affect the liver while also producing autoimmune, dermatological, and renal disease. It is the major cause of mixed cryoglobulinemia, a systemic vasculitis associated with arthralgias, arthritis, Raynaud phenomena, purpura, peripheral neuropathy, hypocomplementemia, and kidney disease. Renal presentations include proteinuria, hematuria, reduced estimated glomerular filtration rate, acute nephritic syndrome, and nephrotic syndrome; the most frequent renal lesion is type I membranoproliferative glomerulonephritis, also called cryoglobulinemic glomerulonephritis.

Earlier treatment sought to remove circulating cryoglobulins or suppress their production through plasma exchange, cyclophosphamide, and corticosteroids. These approaches could control the acute phase but were often poorly tolerated. More importantly, immunosuppression could cause an increase in HCV RNA, potentially worsening HCV-related liver disease. Rituximab offers a more selective strategy: it is a chimeric monoclonal antibody directed against CD20, and therefore directly targets B cells involved in the clonal immune response underlying mixed cryoglobulinemia and HCV-related cryoglobulinemic membranoproliferative glomerulonephritis.

Early Clinical Evidence

Two patients with HCV-related cryoglobulinemic membranoproliferative glomerulonephritis received four weekly rituximab doses of 375 mg/m2 after failing conventional treatment, including interferon-α, plasma exchange, steroids, and either cyclophosphamide or 2-chlorodeoxyadenosine. One patient, whose nephritis had begun recently, showed a rapid response marked by disappearance of proteinuria and inactive urinary sediment. The second patient did not improve after treatment was stopped following two infusions because of retinal-artery thrombosis. In the patient who completed the course, HCV RNA changed only minimally, providing no indication of the major viral flare feared with less selective immunosuppression.

A later series treated six patients with HCV-related cryoglobulinemic glomerulonephritis. One received the standard four weekly infusions, while five received that protocol followed by two additional infusions one and two months later. Proteinuria decreased in every patient. Serum creatinine fell in two, rose in one, and remained stable in three. HCV viral load either decreased or remained stable in all six patients. Rituximab was also reported to be effective as first-line therapy for HCV-related type II cryoglobulinemic membranoproliferative glomerulonephritis, extending its role beyond rescue treatment after failure of conventional therapy.

Combination with Antiviral Treatment

The strongest evidence presented concerns treatment that targets both the viral trigger and the downstream B-cell expansion. In a prospective cohort of 93 patients with HCV-related mixed cryoglobulinemia, one group received rituximab at 375 mg/m2 weekly for one month followed by 48 weeks of pegylated interferon-α and ribavirin, while the comparison group received pegylated interferon and ribavirin alone. Across the whole population, complete clinical response occurred in 73.1%, cryoglobulin clearance in 52.7%, and sustained virologic response in 59.1%.

Adding rituximab accelerated clinical improvement and strengthened the renal and immunologic responses. The time to clinical remission was 5.4 months, compared with 8.4 months with antiviral therapy alone. Complete renal response occurred in 80.9% of the combination-treated patients versus 40% of those receiving pegylated interferon and ribavirin alone. Cryoglobulin clearance reached 68.4% with rituximab combination therapy, compared with 43.6% without it, and suppression of the clonal VH1–69-positive B-cell population was also greater. Treatment was generally well tolerated: 11% discontinued because of antiviral therapy, and rituximab did not worsen HCV RNA.

A second study used pegylated interferon and ribavirin for 48 weeks, with or without rituximab. The rituximab-containing regimen consisted of weekly treatment for one month followed by five monthly infusions. Complete response was achieved in 54.5% of patients receiving the combination, compared with 33.3% receiving antiviral therapy alone. Clearance of HCV RNA and conversion of B-cell populations from oligoclonal to polyclonal in the liver, bone marrow, and peripheral blood persisted for up to three years in 83.3% of responders in the combination group, compared with 40% in the antiviral-only group. Cryoproteins nevertheless persisted in some patients despite sustained HCV RNA clearance, showing that virologic control and immunologic recovery do not always proceed together.

Acute Disease, Transplantation, and Limits

During acute severe disease, plasma exchange may be used to remove circulating cryoglobulins and steroid pulses to treat glomerular infiltration abnormalities. Even without controlled randomized comparisons between anti-CD20 therapy and intravenous cyclophosphamide, the evidence summarized here favors rituximab over cyclophosphamide for HCV-related mixed cryoglobulinemia with renal involvement. Its advantage lies in combining a more focused B-cell mechanism with antiviral therapy, while avoiding the pronounced viral amplification associated with broader immunosuppression.

Rituximab was also reported to be effective for de novo cryoglobulinemic membranoproliferative glomerulonephritis in HCV-positive or HCV-negative kidney transplant recipients. The transplant setting, however, changes the balance of benefit and risk: rituximab was associated with a high rate of infectious complications, plausibly because these patients already experience impaired T-cell and B-cell function from post-transplant immunosuppression. The treatment therefore cannot be reduced to a universal protocol. The volume calls for controlled randomized studies to determine its precise indications, optimal dose, and long-term effects on HCV-related liver disease.